| Name | Bavisant |
| Description | Bavisant (JNJ-31001074) is a selective and orally active Human H3 receptor antagonist. Bavisant can be used in research on mechanisms of action, involving wakefulness and cognition and the treatment for ADHD. |
| In vivo | Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2, and -12.2 in the Bavisant 1 mg/day, 3 mg/day, and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo, and hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed[1]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.07 mM), Sonication is recommended.
DMSO : 13 mg/mL (39.46 mM), Sonication is recommended.
|
| Keywords | wakefulness | Neurological disorders | JNJ31001074 | JNJ 31001074 | Inhibitor | inhibit | Human H3 receptor | HistamineReceptor | Histamine Receptor | cognition | Bavisant | attention-deficit hyperactivity disorder | ADHD |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
